180 results on '"Murakami, Mark A"'
Search Results
2. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
3. Signalling input from divergent pathways subverts B cell transformation
4. Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease
5. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).
6. Distinction of lymphoid and myeloid clonal hematopoiesis
7. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
8. Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma
9. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
10. CTIM-37. A PILOT STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL AND SCNSL)
11. CTIM-39. A PHASE 1B STUDY OF PEMBROLIZUMAB, IBRUTINIB AND RITUXIMAB IN RECURRENT/REFRACTORY (RR) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
12. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma
13. P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY
14. Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
15. S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
16. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
17. Protein re-surfacing of E. coli L-Asparaginase to evade pre-existing anti-drug antibodies and hypersensitivity responses
18. Cell Mass and Stiffness As Integrative Biomarkers of Cell State in Mantle Cell Lymphoma
19. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
20. Recent Developments in Eminent Domain: Public Use
21. CANCER MODELS: The next best thing
22. Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane
23. Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia
24. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults
25. Protein re-surfacing of E. coli L-Asparaginase to evade preexisting anti-drug antibodies and hypersensitivity responses.
26. Toward rational therapy for mantle cell lymphoma
27. Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
28. A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults
29. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults
30. A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL
31. Of woodchucks and prune yards: a view of judicial takings from the trenches.
32. Use of signaling pathways as therapeutic targets for blood cancer
33. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples
34. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
35. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis
36. Abstract IA20: Aberrant leukemic developmental hierarchies and MRD-specific targeting informed by single-cell biophysical and molecular profiling
37. Signaling input from divergent pathways subverts malignant B-cell transformation
38. Justice Ruth Bader Ginsburg and gender discrimination.
39. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
40. Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation
41. Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy
42. Abstract 2450: Single-cell profiling reveals programs mediating oncogenic kinase-independence and minimal residual disease in BCR-ABL-rearranged acute lymphoblastic leukemia
43. Targeting minimal residual disease: a path to cure?
44. High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays
45. Targeting minimal residual disease: a path to cure?
46. The next best thing
47. T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development
48. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
49. An ED pilot intervention to facilitate outpatient acute care for cancer patients
50. High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.